Johnson & Johnson (J&J) announced that sales for fiscal year 2023 reached $85.1 billion, up 6.5% year-on-year.

Net income for the year was $13.2 billion, down 18.6%, with EPS of $5.2, down 15.3%.
On an adjusted basis, net income came to $25.4 billion (+6.8%), for EPS of $9.92 (+11.1%).

Fourth-quarter sales rose by 7.3% to $21.4 billion, while adjusted EPS was $2.29 (+11.7%).

The laboratory also confirmed its 2024 guidance, targeting sales growth of between 5% and 6% and adjusted EPS of between $10.55 and $10.75.


Copyright (c) 2024 CercleFinance.com. All rights reserved.